Navigation Links
Biodesix Completes Series C Financing and Receives Grant
Date:11/10/2010

nical utility with additional targeted oncology therapies and for other tumor types such as colorectal, breast, and head and neck cancers.

About VeriStrat

VeriStrat is a serum proteomic test that predicts response to a specific targeted therapy, erlotinib, in patients with advanced NSCLC.  Identifying patients likely to benefit from erlotinib helps physicians personalize therapy and may improve patient outcomes.  Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment.  VeriStrat has been validated in clinical studies with over 1500 patients.  Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other targeted therapies. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix

Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care.  In 2009, Biodesix launched VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer.  VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient's condition or likely outcome in response to therapy.  The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies. For more information about Biodesix, please visit the Company's website
'/>"/>

SOURCE Biodesix Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PDL BioPharma Completes Exchange to Retire $92.0 Million of 2.00% Convertible Notes Due August 2012
2. BioMed Realty Trust Completes South San Francisco Portfolio Acquisition
3. University of Hawaii completes 3-year investigation of military munitions sea disposal site
4. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
5. CoreLab Partners Completes First TQT Study in Japan
6. ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial
7. PDL BioPharma Completes October 1 Special Dividend Payment
8. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
9. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
10. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
11. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... technology professionals often face the challenge of delivering ... maximize both storage and bandwidth efficiency, while providing ... announced SecureZip, a new family of products designed ... in a cross-platform environment. The company also introduced ...
... Sanyo have announced they will work together to produce ... ,Sanyo will be working with Rayovac's I-C3 technology, which the ... in 15 minutes. I-C3, or In-Cell Charge Control, is a ... regulates the charging mechanism, rather than allowing the charger free ...
... when entrepreneur Ken Schlager started a company, he looked ... This time around, Schlager is turning to the Center ... he launches a cutting-edge technology that applies electromagnetic fields ... has developed a process that oxidizes wastewater and removes ...
Cached Biology Technology:PKWare launches new enterprise product line, adds new features to PKZip 2PKWare launches new enterprise product line, adds new features to PKZip 3CTT - Bridging the states entrepreneurial gap 2CTT - Bridging the states entrepreneurial gap 3
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
(Date:7/30/2014)... awarded the Scientific Committee on Antarctic Research,s (SCAR) ... SCAR, an inter-disciplinary international science body, initiates, develops ... the Antarctic region, and on the role of ... organisation also provides scientific advice about Antarctica to ... region. , The medal is open internationally to ...
(Date:7/30/2014)... a multitude of cells types. Researchers would like to understand ... mature cells that make up the organs and other structures ... long chains of sugars that dangle from proteins on surfaces ... California, San Diego, has created synthetic molecules that can stand ... manipulated to direct the process, they report in the ...
Breaking Biology News(10 mins):
... is a well-known cause of cardiovascular disease, research from the ... revealed that the body,s obesity hormones adiponectin - are ... Our skeleton is more than just bones, vertebrae ... is constantly linked to our brain, our muscles and our ...
... LANSING, Mich. Discovering new treatments and battling dangerous ... researchers targeting the genetic disorder cystic fibrosis with projects ... research studies, with support from a $110,000 grant from ... and Translational Sciences Institute, expand the relationship between the ...
... 1st, 2011) Policy decisions and poor management have ... national security, according to an article available today in ... Scientists, published by SAGE. The article calls into question ... scientists for the decline. , According to George Mason ...
Cached Biology News:4 projects target cystic fibrosis with Hunt for a Cure funds 2Structure, not scientists to blame for Los Alamos failings 2Structure, not scientists to blame for Los Alamos failings 3
... Development kit contains the basic components required ... measure natural and recombinant rat L-Selectin in ... kit contains sufficient materials to run ELISAs ... the following conditions are met: ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Request Info...
Biology Products: